Use of monoclonal antibodies to recognise osteoclasts in routinely processed bone biopsy specimens

N A Athanasou, B Puddle, J Quinn, C G Woods

Abstract
In decalcified (5% nitric acid) and undecalcified (glycol-methacrylate or resin embedded) routinely processed bone specimens osteoclasts against resorbing surfaces were identified with monoclonal antibodies directed against leucocyte common antigen (LCA) (PD7/26, 2B11), CD68 (KP1), and gpIIa (Y2/51) but not against HLA-DR (CR3/43 and Ta11B5). Mononuclear cells on resorbing surfaces and occasional mononuclear cells against or near resting surfaces showed a similar pattern of reactivity. This study shows that immunohistochemistry is a sensitive and useful technique for identifying osteoclasts in routinely processed bone specimens. It also suggests a role for mononuclear cells (possibly pre-osteoclasts) in bone resorption.

Recognition of osteoclasts in bone biopsy specimens is essential for accurate diagnosis of metabolic bone disease as well as some congenital, inflammatory, and neoplastic lesions of bone. Their identification is facilitated by the use of histochemical markers such as tartrate resistant acid phosphatase or the vitronectin receptor. Neither marker is specific for osteoclasts and both require use of fresh or undecalcified material, or fixation, or processing schedules not routinely used in most histopathology laboratories.

The osteoclast antigenic phenotype is now well characterised. Osteoclasts are known to express leucocyte common antigen (LCA), and a restricted set of macrophage antigens. In this study we have identified several monoclonal antibodies which react with osteoclasts in decalcified and undecalcified bone specimens routinely processed for bone histology.

Methods
Material consisted of cases retrieved from the files of the Nuffield Orthopaedic Centre and John Radcliffe Hospital Pathology Departments. These included 15 cases of osteoarthrits of the femoral head fixed for 12–24 hours in 10% buffered formal saline followed by decalcification overnight in 5% nitric acid. Blocks taken for histological examination were processed routinely, embedded in paraffin wax, and sectioned at 5 μm. Ten decalcified and undecalcified bone biopsy specimens known to contain osteoclasts were also examined. Decalcified specimens were processed as above. Undecalcified specimens were embedded in Spurr’s resin and glycol methacrylate or methyl methacrylate. In each case formalin fixation was followed by dehydration through graded acetone and water. Infiltration of monomer was achieved using graded resin and acetone followed by two changes of absolute resin. Polymerisation of the methacrylate resins was achieved by the addition of N-N-dimethylaniline at 4°C. Spurr’s resin was polymerised by the addition of S-1 catalyst and incubation at 50°C overnight. All sections were cut at 5 μm on a Reichert Jung Autocut MK IV and collected on L-polyllysine (Sigma) coated slides. Staining of the methacrylate section was carried out with the resin in situ. Spurr’s resin was removed before staining using potassium ethoxide with subsequent rinsing in two changes of absolute alcohol.

Monoclonal antibodies used in this study are shown in the table. An indirect immunoperoxidase method was the immunohistochemical procedure used in this study. Trypsinisation was carried out for 15 minutes before immunohistochemical staining with monoclonal antibodies KP1 and Y2/51. Using this protocol, no immunohistochemical reaction was produced in sections of methylmethacrylate embedded bone biopsy specimens; this indicates that embedding and processing with this resin is not suitable for indirect immunoperoxidase monoclonal antibody staining.

Results
Several monoclonal antibodies stained antigens known to be present on osteoclasts in fixed, decalcified routinely processed tissues (table). These included PD7/26, 2B11 (both recognising LCA), KP1 (anti-CD68) and Y2/51 (anti-CD61) (fig 1). Antibodies against HLA-DR, CR3/43, and Ta11B5 did not stain osteoclasts or other bone cells but reacted with mononuclear cells in the intertrabecular marrow.

Immunoperoxidase staining with the above osteoclast reacting antibodies was highly specific with a membrane reaction noted with antigens against LCA antibodies (fig 1A) and Y2/51, and a cytoplasmic reaction with KP1 (fig 1B). Osteoblasts, osteocytes, adipocytes and periosteal fibroblasts were unstained. A variable proportion of haemopoietic marrow cells as well as mononuclear inflammatory cells in osteoarthritic subchondral bone cysts reacted with LCA antibodies and KP1. Y2/51 also
Monoclonal antibodies used in this study and osteoclast reaction

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reference</th>
<th>Antigenic determinants</th>
<th>Osteoclast reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD7/26</td>
<td>10</td>
<td>CD45: Leucocyte common antigen</td>
<td>+ +</td>
</tr>
<tr>
<td>2B11</td>
<td>10</td>
<td>CD68-like macrophage-associated antigen</td>
<td>+ +</td>
</tr>
<tr>
<td>KP1</td>
<td>11</td>
<td>CD61-gpIIIa (β3 integrin)</td>
<td>+</td>
</tr>
<tr>
<td>Y2/51</td>
<td>12</td>
<td>HLA-DR</td>
<td>-</td>
</tr>
<tr>
<td>CR3/43</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tal1B5</td>
<td>14</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

+ + strong reaction; + weak reaction; - no reaction.

stained some narrow mononuclear cells and strongly stained megakaryocytes and platelets as well as vascular endothelium. In addition to osteoclasts lying in resorption lacunae of cortical or lamellar bone, these antibodies also reacted with mononuclear cells lying against the resorbing bone surface (fig 1). Positively stained mononuclear cells were noted not only in areas of active resorption, in which osteoclasts were also present, but were also found immediately beneath or occasionally among flattened lining cells lining a bone trabecula in areas not undergoing bone resorption (fig 2). In areas of active bone formation, where plump osteoblasts lined the surface of a bone trabecula, these cells were not present. Serial sections were undertaken to determine whether this staining represented a true mononuclear cell or part of a multinucleated osteoclast; this confirmed the presence of true mononuclear cells on these resorbing and resting bone surfaces.

PD7/26, KP1 and Tal1B5 also clearly stained cells in undecalcified glycol-methacrylate and Spurr's resin-embedded bone biopsy specimens (fig 3). The pattern of immunohistochemical staining was similar to that seen in decalcified specimens. KP1 and PD7/26 stained osteoclasts and mononuclear elements lying against resorbing surfaces, stromal macrophages, and some haemopoietic elements, while Tal1B5 did not react with osteoclasts or mononuclear cells lying against bone trabecula.

Discussion
This study has shown that it is possible to use immunohistochemical techniques to identify osteoclasts by their characteristic antigenic phenotype in routinely processed decalcified and undecalcified specimens submitted for histological examination. Osteoclast expression of LCA, CD68, and gp111a was detected using monoclonal antibodies PD7/26, 2B11, KP1 and Y2/51 and absence of HLA-DR detected with monoclonal antibodies Tal1B5 and CR3/43. Mononuclear cells lying against resorbing surfaces and near resting bone surfaces also showed a similar pattern of antibody staining.

Current markers for the histochemical or immunohistochemical identification of osteoclasts (such as tartrate resistant acid phosphatase, vitronectin receptor) require the use of
undecalcified material and specialised fixation or processing schedules. One of the major advantages of immunohistochemical identification of osteoclasts with the above antibodies is that this can be carried out on formalin fixed, routinely processed decalcified and undecalcified bone specimens. Recognition of osteoclastic activity and quantitation of the area or extent or resorptive activity in bone biopsy specimens for metabolic bone disease should be facilitated by this method of osteoclast identification. Distinction of osteoclasts from tumour giant cells in conditions such as osteosarcoma is also made possible by this technique, particularly as specialised fixatives are not routinely used for processing of biopsy specimens or specimens of bone tumours. These antibodies identifying leucocytes or macrophage antigens are also useful for determining the nature of both mononuclear and multinucleated cells in highly cellular, inflammatory, vascular or neoplastic lesions of bone where it may occasionally be difficult to distinguish between stromal and reactive cells.

Mononuclear cells with a similar antigenic phenotype to that of osteoclasts (HLA-DR negative, LCA positive, CD68, gpIIIa positive) were found against active trabecular resorption surfaces as well as scattered among flattened mononuclear cells lining resting trabecular surfaces. This suggests that mononuclear cells also participate in bone resorption. Although osteoclasts are known to be the principal cell involved in bone resorption, a role for mononuclear cells in the resorptive process, particularly macrophage-like cells, has often been proposed. As osteoclasts are known to be formed by fusion of mononuclear osteoclast precursors (pre-osteoclasts) in the bone, it is also possible that the above antibodies are identifying some mononuclear cells which are destined to fuse to form osteoclast polykaryons. The presence of KP1 positive mononuclear phagocytes among bone lining cells, which appear flattened and line trabeculae showing no evidence of bone resorption or bone formation, also raises the possibility that mononuclear preosteoclasts are normally scattered among, or lie close to, resting bone surfaces.

We thank Mis L Watts for typoing the manuscript and Dr K Pulford and Dr D Y Mason for kindly supplying the antibodies used in this study. We also acknowledge the advice and technical help of Professor S L Teitelbaum and Professor M D Fallon. NAA was an Arthritis and Rheumatism Council Fellow in Pathology.

Use of monoclonal antibodies to recognise osteoclasts in routinely processed bone biopsy specimens.
N A Athanasou, B Puddle, J Quinn and C G Woods

doi: 10.1136/jcp.44.8.664

Updated information and services can be found at:
http://jcp.bmj.com/content/44/8/664

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/